[go: up one dir, main page]

PE20091810A1 - Pirimidin-5-carboxamidas sustituidas 281 - Google Patents

Pirimidin-5-carboxamidas sustituidas 281

Info

Publication number
PE20091810A1
PE20091810A1 PE2009000557A PE2009000557A PE20091810A1 PE 20091810 A1 PE20091810 A1 PE 20091810A1 PE 2009000557 A PE2009000557 A PE 2009000557A PE 2009000557 A PE2009000557 A PE 2009000557A PE 20091810 A1 PE20091810 A1 PE 20091810A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
alkyl
pyrimidin
carboxamide
cyclopropyl
Prior art date
Application number
PE2009000557A
Other languages
English (en)
Inventor
Adrian Liam Gill
Andrew Leach
Martin Packer
James Stewart Scott
John Gibbin Swales
Paul Robert Owen Wittamore
Pernilla Sorme
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091810(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091810A1 publication Critical patent/PE20091810A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRIMIDIN-5-CARBOXAMIDAS DE FORMULA (1) DONDE Q ES UN ENLACE SENCILLO, O, S O N(R8), DONDE R8 ES H, ALQUILO(C1-C4), CICLOALQUILO(C3-C5), ENTRE OTROS; R1 ES ALQUILO(C1-C6), ALQUENILO(C2-C6), ALQUINILO(C2-C6), CICLOALQUILO(C3-C7), ENTRE OTROS; R2 ES CICLOALQUIL(C3-C7)-(CH2)m- O POLICICLOALQUIL(C6-C12)-(CH2)m- CON 1 O 2 HETEROATOMOS DE N, O U S, DONDE m ES DE 0 A 2; R3 ES H, ALQUILO(C1-C4), CICLOALQUILO(C3-C5), ENTRE OTROS; R4 ES H, R10, -OR10, -SR10, ENTRE OTROS, DONDE R10 ES ALQUILO(C1-C6), ALQUINILO(C2-C6), CICLOALQUILO(C3-C7), ARILALQUILO(C1-C3), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-CICLOPROPIL-N-[(2S,5R)-5-HIDROXIADAMANTAN-2-IL]-2-MORFOLIN-4-ILPIRIMIDIN-5-CARBOXAMIDA, 4-CICLOPROPIL-N-((2S,5R)-5-HIDROXI-2-ADAMANTIL)-2-METILPIRIMIDIN-5-CARBOXAMIDA, 4-CICLOPROPIL-N-((2S,5R)-5-HIDROXI-2-ADAMANTIL)PIRIMIDIN-5-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA 11-B-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 (11BHSD1) SIENDO UTILES PARA EL TRATAMIENTO DE LA DIABETES, OBESIDAD, OSTEOPOROSIS, GLAUCOMA
PE2009000557A 2008-04-22 2009-04-22 Pirimidin-5-carboxamidas sustituidas 281 PE20091810A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4683608P 2008-04-22 2008-04-22
US14020108P 2008-12-23 2008-12-23

Publications (1)

Publication Number Publication Date
PE20091810A1 true PE20091810A1 (es) 2009-12-23

Family

ID=40810517

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000557A PE20091810A1 (es) 2008-04-22 2009-04-22 Pirimidin-5-carboxamidas sustituidas 281

Country Status (24)

Country Link
US (1) US20090264401A1 (es)
EP (1) EP2271629A1 (es)
JP (1) JP2011518216A (es)
KR (1) KR20110002475A (es)
CN (1) CN102066335A (es)
AR (1) AR071387A1 (es)
AU (1) AU2009239794A1 (es)
BR (1) BRPI0910734A2 (es)
CA (1) CA2719936A1 (es)
CL (1) CL2009000967A1 (es)
CO (1) CO6321254A2 (es)
CR (1) CR11750A (es)
DO (1) DOP2010000323A (es)
EA (1) EA201001669A1 (es)
EC (1) ECSP10010561A (es)
IL (1) IL208405A0 (es)
MX (1) MX2010011591A (es)
NI (1) NI201000179A (es)
PE (1) PE20091810A1 (es)
SV (1) SV2010003713A (es)
TW (1) TW200948789A (es)
UY (1) UY31774A (es)
WO (1) WO2009130496A1 (es)
ZA (1) ZA201006993B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI399367B (zh) 2005-11-21 2013-06-21 Shionogi & Co 具有Ｉ型１１β羥基類固醇脫氫酶抑制活性之雜環化合物
TW200827346A (en) * 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
MX2009012283A (es) 2007-05-18 2009-11-25 Shionogi & Co Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
JP2011510966A (ja) * 2008-02-04 2011-04-07 アストラゼネカ アクチボラグ ４−［４−（２−アダマンチルカルバモイル）−５−ｔｅｒｔ−ブチル−ピラゾル−１−イル］安息香酸の新規な結晶形態
AR078673A1 (es) * 2009-10-20 2011-11-23 Astrazeneca Ab Pirimidinas sustituidas con adamantiliminocarbonilo como inhibidores de 11-b-hsd1 826
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
RU2697712C2 (ru) 2011-04-22 2019-08-19 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
JP5697800B2 (ja) * 2011-07-21 2015-04-08 シュエンジュウ・ファーマ・カンパニー・リミテッド 複素環置換ピリミジン化合物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
CA2870019C (en) 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
WO2015123003A1 (en) * 2014-02-14 2015-08-20 Warrell Raymond P Bifunctional compounds and use for reducing uric acid levels
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
CN107108526A (zh) 2015-01-22 2017-08-29 R·P·小沃勒尔 双功能化合物及用于降低尿酸水平的用途
CN104649981A (zh) * 2015-02-11 2015-05-27 佛山市赛维斯医药科技有限公司 一种含嘧啶结构的对称环己烷羧酸苄基酰胺类双靶点抑制剂、制备方法及用途
CN104592131A (zh) * 2015-02-11 2015-05-06 佛山市赛维斯医药科技有限公司 含嘧啶结构的对称环己烷羧酸苄基酰胺类化合物及用途
CN104628656A (zh) * 2015-02-11 2015-05-20 佛山市赛维斯医药科技有限公司 一类含嘧啶结构的对称环己烷羧酸酰胺类双靶点抑制剂及用途
CN104649980A (zh) * 2015-02-11 2015-05-27 佛山市赛维斯医药科技有限公司 含嘧啶结构的对称环己烷羧酸酰胺类sglt2/sglt1双靶点抑制剂、制备方法及用途
EP3405183A4 (en) 2016-01-18 2019-12-11 Arisan Therapeutics Inc. ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
TWI772309B (zh) 2016-06-30 2022-08-01 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途(二)
EP3478295A4 (en) 2016-07-01 2019-12-04 G1 Therapeutics, Inc. SYNTHESIS OF N- (HETEROARYL) -PYRROLO [3,2-D] PYRIMIDIN-2 AMINES
EP3481819B1 (en) 2016-07-06 2022-06-01 Acquist LLC Compounds and their use for reducing uric acid levels
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
CN112839657B (zh) 2018-08-24 2025-07-25 法码科思莫斯控股有限公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
TW202130623A (zh) * 2019-12-02 2021-08-16 美商富曼西公司 用於合成2-硫烷嘧啶的製程
TWI794994B (zh) * 2020-09-25 2023-03-01 大陸商上海美悅生物科技發展有限公司 嘧啶甲醯胺類化合物及其應用
CN115141147B (zh) 2022-08-24 2023-09-12 绍兴上虞新银邦生化有限公司 一种n-甲基-3-取代甲基-4-吡唑甲酰胺衍生物的合成方法
AU2023337160A1 (en) * 2022-09-08 2025-03-20 Changchun Genescience Pharmaceutical Co., Ltd. Kif18a inhibitor compound, and pharmaceutical composition and preparation method therefor and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (es) * 1978-02-21 1981-03-27 Delalande Sa
FR2631028B1 (fr) * 1988-05-09 1990-07-13 Cird Adamantyl-2 isothiazoline-4 ones-3, leur procede de preparation et leur utilisation comme agents bactericides et fongicides
DE69304453T2 (de) * 1992-07-07 1997-02-06 Kyowa Hakko Kogyo Kk Pyridin-Derivate und diese enthaltende pharmazeutische Zubereitungen
US7087597B1 (en) * 1999-10-12 2006-08-08 Takeda Pharmaceutical Company Limited Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
JP4178816B2 (ja) * 2001-03-15 2008-11-12 田辺三菱製薬株式会社 医薬組成物
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
JP4629657B2 (ja) * 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
US7459460B2 (en) * 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
JP2008519034A (ja) * 2004-11-03 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節剤としてのピリミジン誘導体および使用方法
EP2527337A1 (en) * 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US20100022589A1 (en) * 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) * 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
WO2009051112A1 (ja) * 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
EP2217232A1 (en) * 2007-11-06 2010-08-18 AstraZeneca AB 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465
JP2011510966A (ja) * 2008-02-04 2011-04-07 アストラゼネカ アクチボラグ ４−［４−（２−アダマンチルカルバモイル）−５−ｔｅｒｔ−ブチル−ピラゾル−１−イル］安息香酸の新規な結晶形態
AR078673A1 (es) * 2009-10-20 2011-11-23 Astrazeneca Ab Pirimidinas sustituidas con adamantiliminocarbonilo como inhibidores de 11-b-hsd1 826

Also Published As

Publication number Publication date
CR11750A (es) 2010-12-15
ECSP10010561A (es) 2010-11-30
CN102066335A (zh) 2011-05-18
EA201001669A1 (ru) 2011-06-30
IL208405A0 (en) 2010-12-30
KR20110002475A (ko) 2011-01-07
AU2009239794A1 (en) 2009-10-29
NI201000179A (es) 2011-12-15
MX2010011591A (es) 2010-11-09
WO2009130496A1 (en) 2009-10-29
AR071387A1 (es) 2010-06-16
JP2011518216A (ja) 2011-06-23
SV2010003713A (es) 2011-02-17
TW200948789A (en) 2009-12-01
EP2271629A1 (en) 2011-01-12
US20090264401A1 (en) 2009-10-22
CA2719936A1 (en) 2009-10-29
CO6321254A2 (es) 2011-09-20
CL2009000967A1 (es) 2010-06-11
DOP2010000323A (es) 2010-12-15
UY31774A (es) 2009-12-14
BRPI0910734A2 (pt) 2015-09-29
ZA201006993B (en) 2012-03-28

Similar Documents

Publication Publication Date Title
PE20091810A1 (es) Pirimidin-5-carboxamidas sustituidas 281
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20091816A1 (es) Inhibidores de bace
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20061084A1 (es) Compuestos derivados de 2-ciano-3-(halo)alcoxi-bencenosulfonamida
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20090362A1 (es) Derivados de piperidina/piperazina como moduladores de dgat
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20050864A1 (es) Compuestos de heterociclilamino como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
MX2011011485A (es) Sulfonamidas nematocidas.
PE20120057A1 (es) Compuestos de tiazolopiridina moduladores de sirtuina
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20080091A1 (es) Derivados de cicloalquilamino como agentes moduladores de s1p
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
PE20121010A1 (es) Derivados de bencimidazol
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20071251A1 (es) Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
PE20091473A1 (es) Heterociclos como inhibidores de esteaoril-coa desaturasa
PE20140102A1 (es) Compuestos de piperidina puenteada tipo quinoxalina sustituida con actividad sobre el receptor orl-1
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
PE20091887A1 (es) Fenoxibenzamidas sustituidas
PE20151281A1 (es) Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3

Legal Events

Date Code Title Description
FC Refusal